Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
about
The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study.African American patients with gout: efficacy and safety of febuxostat vs allopurinol.Comorbidities in patients with crystal diseases and hyperuricemia.Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy.Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive ratsFebuxostat in the management of hyperuricemia and chronic gout: a review.Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4.Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation.Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort.Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-ReviewRole of oxidative stress in the renal abnormalities induced by experimental hyperuricemia.Uric acid and chronic kidney disease: A time to act?Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women.The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population.Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout.Drug treatment of hyperuricemia to prevent cardiovascular outcomes: are we there yet?Gout and its comorbidities: implications for therapy.Hyperuricemia and chronic kidney disease: an enigma yet to be solved.Febuxostat for the chronic management of hyperuricemia in patients with gout.Management of Gout and Hyperuricemia in CKD.N-Propargylamines: versatile building blocks in the construction of thiazole cores.Febuxostat Attenuates Renal Damage besides Exerting Hypouricemic Effect in Streptozotocin-Induced Diabetic Rats.Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery.Central arterial characteristics of gout patients with chronic kidney diseases.Impaired Na+-K+-ATPase signaling in renal proximal tubule contributes to hyperuricemia-induced renal tubular injury.Serum uric acid and renal function in patients with type 1 diabetes: a nationwide study in Brazil.Febuxostat, a novel drug for the treatment of hyperuricemia of goutProbiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage
P2860
Q33634704-69ED8FFA-6744-4EAC-89A0-4445C3EAEAE5Q33988764-F3C45DD4-E23E-44EF-860F-EE0F5200A87FQ34153554-27720BFA-C2D1-4406-82CA-B27162FBD904Q34157725-68C9667A-9562-4176-BBCB-4199FBF8BA44Q34427632-89033ACB-25E0-421D-A496-12AD5CE5A91FQ34581053-C5C27265-A246-46E0-A224-866549FB1DD8Q34658300-2F0C264A-3DEB-4F56-8C22-912F27D0EE05Q34713167-5B6CA592-015F-49DA-84C1-0F4C5390BB66Q35247002-219B8A7D-05E5-4252-BC3B-0F0687CC76F5Q35597582-0AEA6042-472E-46E1-B449-29A5EA8CAD24Q36255567-1F5C749C-883A-4032-BF2F-D81176B77EC3Q36956768-0ACB79C4-2595-4965-A74F-82551FCBFF76Q37195441-D506D3B6-FDCC-42D7-BBA3-E1DEFB682E56Q37350881-78C2DEC3-7C98-4B2B-8233-9591E50867D6Q37463796-57DF4B4D-B051-46CE-A7CD-176DBE6F1F4CQ37506899-72DB95C4-E081-49D1-940B-1BA8240E5C67Q37600805-E6D766EE-3E63-477C-80A2-A158B3B26B9AQ37674063-40BA4B44-10D3-44F3-AFB8-4A4E62E69917Q37702650-5262D328-EDFC-42ED-9658-81574C0141F4Q37972015-423AD825-806A-452C-8B34-5FDA70B82AA6Q38040777-0EA3015C-B962-4F8C-85A9-AF72AC0892E6Q38238942-045D0D18-83C5-48AC-A6CE-8614B6D14927Q38760404-97A4D8AE-2D63-4B3E-B297-7A5E5359E146Q38812962-5EBA5873-8A47-4637-9FB1-C54C7F5BB060Q39294560-BFAFB6A8-AC89-4B63-823F-82DEDFA20BC9Q41871493-C70D7C61-6DA5-4624-8EBE-53F68BA4EB94Q41974155-8F897C55-9FC7-4115-AEB7-0DEA0131D00EQ42152252-05625946-A864-43DA-8101-51B41B843390Q43600725-04C17DC8-15A5-401E-BC4C-98291EF81199Q53832266-D4703196-0E6B-497D-A77E-66B24AC2B4C6Q54123515-DCEFDEA2-D6B2-4AA0-A357-947284B0C85CQ55332246-399A28F9-DD1B-402F-9898-CFDA64FF83FAQ57076791-E5A50EC3-1D1A-4B11-90EF-5709F6F57119Q58708791-6F4987AC-4027-4363-AB42-2C24C4F8DF48
P2860
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@ast
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@en
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@nl
type
label
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@ast
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@en
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@nl
prefLabel
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@ast
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@en
Treatment with the xanthine ox ...... n experimental hyperuricaemia.
@nl
P2093
P356
P1476
Treatment with the xanthine ox ...... in experimental hyperuricaemia
@en
P2093
Carmen Avila-Casado
Edilia Tapia
Richard J Johnson
Virgilia Soto
P304
P356
10.1093/NDT/GFM783
P407
P577
2007-11-29T00:00:00Z